Cyproterone acetate in the therapy of prostate carcinoma

Archivio Italiano di Urologia e Andrologia

Volumn 77, Issue 3, 2005, Pages 157-163

  Torri, Valter ^a   Floriani, Irene ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cyproterone acetate; Prostatic carcinoma

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GLUCOCORTICOID RECEPTOR; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NILUTAMIDE; PROGESTERONE RECEPTOR; TRIPTORELIN;

CANCER INCIDENCE; CARDIOTOXICITY; CASTRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GYNECOMASTIA; HOT FLUSH; HUMAN; LIVER TOXICITY; PROSTATE CARCINOMA; RECEPTOR AFFINITY; REVIEW; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 28344456094     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Mahal K, Hernandez J, Basler JW, Thompson IM. What's New in the field of prostate cancer chemoprevention? Curr Oncol Rep. 2004; 6:237
2. Catalona WJ, Scott WW. Carcinoma of the prostate: a review. J Urol 1978; 119:1
3. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986; 7:67
4. Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: Pharmacological base and clinical experience. Exp Clin Endocrinol 1991; 98:71
5. Varenhorst E, Wallentin L, Carlstrom K. The effects of orchiectomy, estrogens, and cyproterone acetate on plasma testosterone, LH and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol 1982; 16:31
6. Faredin I, Toth I, Oszlanczy J, et al. In vitro study of rat prostate 5a-reductase activity and its inhibition. Int Urol Nephrol 1992; 24:145
7. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; Suppl 4:129
8. Associazione Italiana di Oncologia Medica. Linee Guida per il Carcinoma della Prostata. Intermedia Editore Healthcare Communication Network, 2004
9. Blom JHM. Clinical parameters for the transition to endocrine independence of prostate cancer. In: Berns et al, editors. Mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnforth: Parthenon, 1991
10. Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol 1979; 5:303
11. El Etreby MF, Habenicht U-F, Louton T, et al. Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicles, and adrenal glands of adult male rats. Prostate 1987; 11:361
12. Barrandel LB, Faulds D. Ciproterone. Rassegna sul profila farmacologico e sulla efficacia terapeutica nel carcinoma della prostata. Drugs & Aging ottobre 2000.
13. Geller J, Vazakas G, Fruchtrnan B, et al. The effect of cyproterone acetate on advanced carcinoma of the prostate. Surg Gynecol Obstet 1968; 127:748
14. Moffat LEF. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990; 18 Suppl. 3:26
15. Pavone-Macaluso M, de Voogt HJ, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136:624
16. Seidenfeld J, Sarnson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Int Med 2000; 162:566
17. Jacobi GH, Altwein JE, Kurth KH, et al. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol 1980; 52:208
18. Porter AT, Venner PM. The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer the Canadian perspective. Prog Clin Biol Res 1990; 359:231
19. Goldenberg SL, Klotz L. Randomized Mal of neoadjuvant androgen ablation prior to radical prostatectomy: 24-month post-treatment PSA results. Molec Urol 1998; 2:165
20. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S; Canadian Uro-Oncology Group. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003; 170:791
21. Pescatore D, Giberti C, Martorana G, et al. The effect of cyproterone acetate and orchiectomy on metastases from prostatic cancer. Eur Urol 1980; 6:149
22. Tobelem G, Arvis G. Cyproterone acetate. Interest in treatment of prostatic cancer. A study of 45 cases (in French). Therapie 1988; 43:179
23. Robinson MRG. A further analysis of European Organization for Research and Treatment of Cancer Protocol 30805. Cancer 1993; 72 (Suppl 12):3855
24. Jorgensen T, Tveter KJ and the members of the SPCG-2 group. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No.2. Eur Urol 1993; 24:466
25. Sander S, Nissen-Meyer R, Aakvaag A. Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 1982; 16:193
26. Prostate cancer trialists collaborative group. Maximum androgen blockade in advanced prostate cancer: an overview of randomised trials. Lancet 2000; 355:149
27. Chrisp P, Goa KL. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and clinical use in sex hormone related conditions. Drugs 1991; 41:254
28. Mahler C. Is disease flare a problem? Cancer 1993; 72 (Suppl 12):3799
29. de Voogt HJ. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer. Prostate 1992; (Suppl 4):91
30. Thorpe SC, Azmatullah S, Fellows GJ. A prospective, randomised study to compare goserelin acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of two in the treatment of metastatic prostatic carcinorna. Eur Urol 1996; 29:47
31. de Voogt HJ, Klijin JGM, Studer V, et al. Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial-30843. J Steroid Biochem Mol Biol 1990; 37:965
32. Di Silverio F, Serio M, D'Eramo G, et al. Zoladex vs zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 1990; 18 (Suppl 3):54
33. Schroeder FH, Lock TMTw, Chadha DR, et al. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 1987; 137:912
34. Prezioso D, Lotti T, Montironi R, et al. Role of neoadjuvant treatment in clinically confirmed prostate cancer. Takeda NHT Italian Group. Eur Urol 1995; 35 (Suppl 1):17
35. Klotz LH, Kerr HW, Morse MJ, et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58:2546
36. Da Silva C, Bono A, Whelan P, et al. Phase III study of intermittent MAB versus continuous MAB. International Cooperative Study. Eur Urol 1999; 35 (Suppl 2):14
37. Eaton AC, McGuire N. Cyproterone acetate in treatment of postorchidectomy hot flushes. Double-blind cross-over trial. Lancet 1983; 2:1336
38. Krürner P, Andrzejah-Nolten N, Kallischnig G, et al. Prevention of hot flushes with CPA in the hormonal treatment of prostatic cancer. Results of a placebo-controlled double-blind trial. Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment; 1992
39. de Voogt HJ, Smith PH. Pavone-Macaluso M, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estrarnustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1986; 135:303
40. Wallentin L, Varenhorst E. Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma. J Clin Endocrinol Metab 1980; 51:1118
41. Gillat DA, Bolton CH, Chadwick D, et al. Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol 1993; 71:728
42. Paisey RB, Kadow C, Bolton C, et al. Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 1986; 79:210
43. Varenhorst E, Risberg B. Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate. Invest Urol 1981; 18:355-7
44. Editorial. Gonadotrophin releasing hormone analogues for advanced prostate cancer. Drug Ther Bull 1992; 30:65
45. Schroder PH, Collette L, de Reijke TM, et al. Prostate cancer treated by anti-androgens: is sexual function preserved? Br J Cancer 2000; 82:283
46. Schroder FH, Whelan P, de Reijke TbM, et al. Metastatic prostate cancer: a randomized study cyproterone acetate versus flutamide EORTC 30892. Report from the XV Congress of the European Association of Urology, Brussel, Belgium, April 12-15, 2000
47. Schiirmeyer Th, Graff J, Senge Th, et al. Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients. Acta Endrocrinol 1986; 111:3607
48. Parys BT, Hamid S, Thomson RG: Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 1991; 67:312